It combines two medicines ... a new therapeutic approach to reducing heart attacks

A scientific study, the largest of its kind so far, has shown that patients who run the risk of heart attacks and strokes should receive an immediate treatment, combining medicine ‘statin’ and ‘EZEITIMIB’, instead of relying on the first alone. This therapeutic approach can save thousands of lives annually by preventing deaths caused by cardiovascular disease. This study was published in ‘Mayo Clinic’, and included an extensive analysis of 108 thousand and 353 patients, from 14 different studies, and these patients were either a high risk for heart attack, or a stroke, or they were already subjected to one of these cardiovascular events. The treatment of a heart attack, and the results showed that the combination of ‘EZEITIMIB’ and ‘statin’ in high doses led to a significant decrease in harmful cholesterol levels (LDL-C), which in turn reduced the risk of death by 19%, and reduced the deaths of cardiovascular disease by 16%. The cases of large cardiovascular events and strokes also dropped by 18% and 17% respectively, compared to the use of statin alone. Statin is a category of cholesterol medicine, which is mainly used to reduce harmful cholesterol levels (LDL-C) in the blood, which helps prevent cardiovascular disease, such as heart attacks and strokes. The statins work by obstructing an enzyme called HMG coa-reductase, which plays a major role in producing cholesterol in the liver, and when inhibited, the amount of cholesterol produced by the liver decreases, resulting in low levels of harmful cholesterol in the blood. In addition to harmful cholesterol, ‘statins’ have other benefits, such as increasing levels of good cholesterol (HDL-C), and reduce triglycerides. It also has anti -inflammatory effects that help stabilize plaques in the veins, reducing the risk of split and the formation of lumps. Although “statins” are generally safe, it can cause some side effects, such as muscle pain, high liver enzymes, or a slight increase in the risk of type 2 diabetes. However, the benefits of preventing heart disease are better than these potential risks for most patients. As far as the ‘Ezitimib’ is concerned, it reduces the absorption of cholesterol in the small intestine, and is often used with statins to increase the effectiveness of lowering harmful cholesterol (LDL-C) in patients who cannot achieve the necessary cholesterol levels using statins. The lowering of cholesterol levels and the new study showed that joint treatment reduced harmful cholesterol levels with an additional 13 milligram per decillin blood compared to sixty alone. This improvement has increased the chances of achieving the ideal goal of reducing the level of harmful cholesterol to less than 70 milligrams per desierfully by 85%. The analysis, which enabled a direct comparison between the different treatment systems in the study, confirmed these results more, as it showed a 49% decrease in the death rate of all causes, and a 39% decrease in large cardiovascular events, compared to the treatment of Sixtin in high doses alone. “The joint treatment is safe and effective, and there were no significant differences in side effects or the treatment between groups,” said the lead author of the study, MacG Banash, professor of heart disease at the University of John Ball II Catholic University in Lublin, Poland. Panash added that “network analysis showed a 44% reduction in the risk of treatment in patients who received joint treatment compared to the treatment of Sixtin alone.” So far, there has been a golden standard conflicting opinions on whether joint treatment should be given immediately to lower cholesterol to patients who are at risk, or wait to know the effect of statin alone before adding Ezitimib, but this study confirmed that joint treatment should be the ‘gold standard’ to treat these patients, especially after being exposed to serious heart attacks. The study author, Peter Tut, professor of family medicine at the University of Illinois in the United States, said that “the addition of Essetimib to the treatment of Sixtin without waiting, increases the effectiveness of the goals of reducing harmful cholesterol, and significantly reducing the heart health problems and deaths.” TUT added that “this approach does not require additional financing or acceptance of expensive medicine, but that it can reduce the cost of healthcare in the long run by preventing heart attacks and strokes and their complications.” According to the data of the World Health Organization and the American Heart Association, the deaths caused by the high level of harmful cholesterol were highest in Eastern Europe and Central Asia, causing 4.5 million deaths in the world in 2020. Panash added that “cardiovascular disease leads to the lives of about 20 million people used worldwide annually, it can be more than 330 thousand, and it can save more than 330 thousand. To a heart attack, including about 50,000 people in the United States alone.